目的：探究泪道激光联合引流管植入对泪道阻塞患者泪膜破裂时间及角膜荧光素钠染色的影响，以便提高泪道激光联合引流管植入术对患者的治疗效果。

方法：选取2013-01/2015-12在我院进行泪道激光联合泪道引流管植入术治疗的泪道阻塞患者200例200眼，分别在治疗前、术后1mo、拔管后进行眼表评估。检测内容包括患者泪膜破裂时间、泪液分泌量、角膜荧光素钠染色情况及干眼症状问卷等。

结果：患者治疗前、术后1mo、拔管后泪膜破裂时间，三者间比较差异无统计学意义(P>0.05)。患者术后1mo泪液分泌量增加，拔管后泪液分泌量减少，差异有统计学意义(P<0.05)。患者治疗前、术后1mo、拔管后角膜荧光素钠染色评分无明显变化，三者间比较差异无统计学意义(P>0.05)。进行干眼症状问卷显示行泪道激光联合引流管植入术后流泪症状明显改善。

结论：泪道激光联合引流管植入对患者泪膜破裂时间及角膜荧光素钠染色无明显影响，此种手术方式可以使患者术后流泪症状明显改善，在治疗泪道阻塞方面具有重大意义。

AIM: To investigate the effect of lacrimal passage laser combined with drainage tube implantation on tear film rupture time and corneal fluorescein sodium staining in patients with lacrimal duct obstruction so as to improve the therapeutic effect of lacrimal laser combined drainage tube implantation.

METHODS: From January, 2013 to December, 2015, 200 cases(200 eyes)of lacrimal passage obstruction were treated with lacrimal passage laser combined with lacrimal drainage tube implantation in our hospital. Before and 1mo after operation, after the tube was draw out, ocular surface was assessed. The test included tear film rupture time, tear secretion, corneal fluorescein staining and dry eye syndrome questionnaire.

RESULTS: There was no significant difference in tear film rupture time between the two groups before and after 1mo, after the tube was draw out(P>0.05). The amount of tear secretion increased at 1mo after operation and the amount of tear secretion decreased after extubation. The difference was statistically significant(P<0.05). There was no significant difference in the corneal fluorescein staining before and after operation, after extubation(P>0.05). The dry eye symptom questionnaire showed that the tearing laser combined drainage tube implantation significantly improved the tearing symptoms.

CONCLUSION: The lacrimal duct laser combined drainage tube implantation has no significant effect on tear film rupture time and corneal fluorescein sodium staining. This kind of operation can improve the postoperative tearing symptoms of the patients, and is of great significance in the treatment of lacrimal passage obstruction.